LEADER 01989cam0-22006971i-450- 001 990001036620403321 005 20080314095037.0 035 $a000103662 035 $aFED01000103662 035 $a(Aleph)000103662FED01 035 $a000103662 100 $a20001205d1953----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $ay-------001yy 200 1 $aMethods of theoretical physics$fPhilip M. Morse, Herman Feshbach 210 $aNew York [etc.]$cMcGraw-Hill$d1953 215 $a2 v.$d24 cm 225 1 $aInternational series in pure and applied physics 327 1 $a1.: Chapters 1 to 8$a2.: Chapters 9 to 13 610 0 $aFisica matematica 610 0 $aFisica teorica 610 0 $aFisica 676 $a530.15 676 $a515 700 1$aMorse,$bPhilip M.$01448 701 1$aFeshbach,$bHerman$02639 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001036620403321 952 $aC.20-004$b2600$fFI1 952 $a20-006.001F$b561$fFI1 952 $aS.20-021$b3830$fFI1 952 $aS.20-043$fFI1 952 $aS.20-020$fFI1 952 $aS.20-044$fFI1 952 $a20-006F$fFI1 952 $a02 67 D 10$b3760$fFINBN 952 $a02 67 D 9$b3761$fFINBN 952 $a00 L2818(2)$b5585$fDETEC 952 $a04 012-73/1$bPIC/CNR 541/L$fDINCH 952 $a31-A-29$b2501$fMA1 952 $a31-A-28$b2501$fMA1 952 $a05 76 168$b297$fDININ 952 $a05 76 59$b298$fDININ 952 $a04 012-29/2$bIRC 612/L$fDINCH 952 $a04 012-29/1$bCI 6054$fDINCH 952 $a13 B 06 17$b20480$fFINBC 952 $a13 B 06 16$b20479$fFINBC 952 $a04 012-73/2$bPIC/CNR 541/L$fDINCH 952 $a10 B I 71$b4827$fDINEL 952 $a10 B I 72$b4828$fDINEL 959 $aFI1 959 $aFINBN 959 $aDINCH 959 $aMA1 959 $aDININ 959 $aFINBC 959 $aDINEL 996 $aMethods of theoretical physics$9338790 997 $aUNINA LEADER 01116nam a2200301 i 4500 001 991003573349707536 005 20021217152248.0 008 961025s1989 us a b 001 0 eng d 020 $a0306427311 035 $ab11833233-39ule_inst 035 $aLE00303415$9ExL 040 $aDip.to Biologia$beng 082 0 $a616.91$222 245 00$aViral infections of humans :$bepidemiology and control /$cedited by Alfred S. Evans 250 $a3th ed. 260 3 $aNew York :$bPlenum Medical Book Co.,$c1989 300 $axxxix, 829 p. :$bill. ;$c26 cm 500 $aIncludes bibliographical references and index 650 0$aVirus diseases$xEpidemiology 650 0$aVirus diseases$xOccurrence 650 0$aVirus diseases$xPrevention & control 700 1 $aEvans, Alfred S. 907 $a.b11833233$b04-11-10$c18-12-02 912 $a991003573349707536 945 $aLE003 616.91 EVA01.01 (ed. 1989)$g1$i2003000004083$lle003$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i12083963$z18-12-02 996 $aViral infections of humans$9898066 997 $aUNISALENTO 998 $ale003$b01-01-96$cm$da $e-$feng$gus $h0$i1 LEADER 01697nam 2200397 a 450 001 9910696396503321 005 20071217153136.0 035 $a(CKB)5470000002376862 035 $a(OCoLC)184739658 035 $a(EXLCZ)995470000002376862 100 $a20071217d2007 ua 0 101 0 $aeng 135 $aurmn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug testing$b[electronic resource] $eundercover tests reveal significant vulnerabilities in DOT's drug testing program : testimony before the Subcommittee on Highways and Transit, Committee on Transportation and Infrastruture, House of Representatives /$fstatement of Gregory D. Kutz 210 1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2007] 215 $a25 pages $cdigital, PDF file 225 1 $aTestimony ;$vGAO-08-225 T 300 $aTitle from title screen (viewed on Dec. 11 2007). 300 $a"For release ... November 1, 2007." 300 $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548. 320 $aIncludes bibliographical references. 517 $aDrug testing 606 $aDrug testing$xGovernment policy$zUnited States 615 0$aDrug testing$xGovernment policy 700 $aKutz$b Gregory D$01351611 712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Transportation and Infrastructure.$bSubcommittee on Highways and Transit. 712 02$aUnited States.$bGovernment Accountability Office. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910696396503321 996 $aDrug testing$93484066 997 $aUNINA